Genentech playing poker with Alzheimer's?

(Julie Christie got an Oscar nomination last year for playing an Alzheimer's victim in Away from Her Marion Cotillard won for La Vie En Rose.)

Marc Tessier-Lavigne said his group found that APP does the work of "pruning" nerve cells in human embryos, under the command of a compound known as death receptor 6, which regulates nerve development so we end up with normal brains and nerve systems.

It has long been known that APP has a hand in Alzheimer's. It's the source of beta-amyloid plaques, and many recently failed drug trials have been aimed at destroying the plaques.

All Tessier-Lavigne has, then, is the normal use of APP. Why and how it reappears in old age and starts destroying us from the outside in, let alone how to stop it, remain mysteries. Intriguing mysteries but mysteries.

Now for the poker part. As our sister site BNET reports, Roche Holding AG of Switzerland is currently trying to buy the 44% of Genentech it does not already own.

It's the centerpiece of the Roche CEO's argument for a pay raise, and it is stretching every sinew to finance a $42.1 billion bid, promising it will feel quite full if it can pull off the coup.

If the market buys into the importance of Genentech's Alzheimer's work, bidding the stock over the current $86/share Roche offer, the deal could be off.

It seems clear there is a long road from knowing what protein to attack and why to having an effective drug in a clinical trial. How long that road is for Genentech is unclear.

At this writing Genentech was trading at $85.17, about $2 higher than at the moment of the Alzheimer's announcement, but still lower than the Roche offer.

Will Alzheimer's help Genentech get away from Roche? Does it still want to? And who will play Tessier-Lavigne in the movie? Stay tuned.